Vanguard Group Inc Pharvaris N.V. Transaction History
Vanguard Group Inc
- $6.44 Trillion
- Q3 2025
A detailed history of Vanguard Group Inc transactions in Pharvaris N.V. stock. As of the latest transaction made, Vanguard Group Inc holds 19,310 shares of PHVS stock, worth $465,757. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,310Holding current value
$465,757% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding PHVS
# of Institutions
62Shares Held
40.3MCall Options Held
0Put Options Held
0-
General Atlantic LLC New York, NY8.03MShares$194 Million7.09% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA4.41MShares$106 Million85.48% of portfolio
-
Ven Bio Partners LLC San Francisco, CA4.29MShares$103 Million79.45% of portfolio
-
Viking Global Investors LP3.65MShares$88.1 Million0.2% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA3.3MShares$79.7 Million17.44% of portfolio
About Pharvaris N.V.
- Ticker PHVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,766,000
- Market Cap $814M
- Description
- Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...